{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T02:26:06Z","timestamp":1772418366527,"version":"3.50.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007091","name":"RefleXion Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background and purpose<\/jats:title><jats:p>The aim of this study was to determine the prevalence of patients with relapsed or refractory (R\/R) non-Hodgkin lymphoma (NHL) meeting high-risk criteria for early relapse after CD19 CAR T-cell therapy (CART) who have disease encompassable in a standard radiation therapy (RT) plan (defined as &amp;lt;5 malignant lesions) and may benefit from bridging RT prior to CD19 CART.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>This is a single-center, retrospective study of patients with R\/R NHL who received CD19 CART from 2018 to 2022. Eligible patients had pre-apheresis radiologic studies available. All patients were classified by number of lesions and history of high-risk disease criteria: bulky disease \u226510 cm, \u22651 extranodal (EN) sites, LDH \u2265normal, or \u22651 lesion with SUVmax \u226510.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 81 patients with R\/R NHL were evaluated. Based on our definition, 40 (49%) patients would have been eligible for bridging RT, including 38 patients who met high-risk criteria: 31 with \u22651 EN site, 19 had \u22651 lesion with SUVmax \u226510, 16 with bulky disease, and 3 with elevated LDH. At 3 months after CART, ORRs in high-risk patients with &amp;lt;5 lesions, \u22655 lesions, and no lesions on pre-apheresis studies were 76% (CR 69%, PR 7%), 70% (CR 60%, PR 10%), and 80% (CR 80%), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Approximately 47% (38\/81) of patients were classified as at high risk of relapse after CART with disease encompassable in a standard radiation plan and eligible for bridging RT studies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1425506","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T04:19:42Z","timestamp":1724041182000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence of non-Hodgkin lymphoma patients at high-risk of failure after CAR T-cell therapy eligible for bridging radiation therapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Adnan","family":"Danish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Della Pia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Fogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Alkhatatneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Varughese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine A.","family":"Al Feghali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Sinclaire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Marafelias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Zenreich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Hong","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana A.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre H.","family":"Goy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Ip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Rowley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"key":"B1","article-title":"SEER*Explorer: An interactive website for SEER cancer statistics","year":"2023"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1097\/HS9.0000000000000185","article-title":"CAR-T cell therapy in diffuse large B cell lymphoma: Hype and hope","volume":"3","author":"Hopfinger","year":"2019","journal-title":"Hemasphere"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20210098","article-title":"The current and future role of radiation therapy in the era of CAR T-cell salvage","volume":"94","author":"DeSelm","year":"2021","journal-title":"Br J Radiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402","article-title":"International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.06.038","article-title":"Patterns and predictors of failure in recurrent or refractory large B-cell lymphomas after chimeric antigen receptor T-cell therapy","volume":"111","author":"Figura","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.1113","article-title":"Comprehensive bridging radiotherapy for limited pre-CART non-Hodgkin lymphoma","volume":"10","author":"Saifi","year":"2024","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.05.014","article-title":"Bridging radiation therapy before commercial chimeric antigen receptor T-cell therapy for relapsed or refractory aggressive B-cell lymphoma","volume":"108","author":"Wright","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B12","doi-asserted-by":"publisher","first-page":"259.e1","DOI":"10.1016\/j.jtct.2022.12.021","article-title":"Bridging radiation rapidly and effectively cytoreduces high-risk relapsed\/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell therapy","volume":"29","author":"Hubbeling","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.semradonc.2019.12.006","article-title":"Novel radiation therapy paradigms and immunomodulation: heresies and hope","volume":"30","author":"Dutt","year":"2020","journal-title":"Semin Radiat Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00612","article-title":"Radiation, immune checkpoint blockade and the abscopal effect: a critical review on timing, dose and fractionation","volume":"8","author":"Buchwald","year":"2018","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4143\/crt.2022.1460","article-title":"Top ten lessons learned from trials in oligometastatic cancers","volume":"55","author":"Tan","year":"2023","journal-title":"Cancer Res Treat"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B17","article-title":"R: A language and environment for statistical computing","year":"2023"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157540","article-title":"multi-institutional review of bridging radiotherapy prior to chimeric antigen receptor T-cell therapy for B-cell lymphomas","volume":"140","author":"Yegya-Raman","year":"2022","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.12.005","article-title":"Role of radiation therapy in patients with relapsed\/refractory diffuse large B-cell lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"AK","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.648655","article-title":"Radiation and CAR T-cell therapy in Lymphoma: Future frontiers and potential opportunities for synergy","volume":"11","author":"Fang","year":"2021","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000284","article-title":"Radiation priming chimeric antigen receptor t-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma with high tumor burden","volume":"4","author":"Qu","year":"2020","journal-title":"J Immunother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000453","article-title":"Radiotherapy for non-Hodgkin lymphomas","volume":"26","author":"Imber","year":"2020","journal-title":"Cancer J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.07.955","article-title":"analysis of patterns of failure and the role of bridging radiation therapy in patients with relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCLC) treated with CAR\u00a0T-cell therapy","volume":"11","author":"Ravella","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018023119","article-title":"Accelerated, but not conventional, radiotherapy of murine B-cell lymphoma induces potent T cell-mediated remissions","volume":"2","author":"Dutt","year":"2018","journal-title":"Blood Adv"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1788","article-title":"NKG2B-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma","volume":"78","author":"Weiss","year":"2018","journal-title":"Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1425506\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T04:19:47Z","timestamp":1724041187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1425506\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":27,"alternative-id":["10.3389\/fonc.2024.1425506"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1425506","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]},"article-number":"1425506"}}